ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb Read more about ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb
ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) Read more about ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209)
ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting Read more about ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting
ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development Read more about ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development
ICON Forms Strategic Alliance With Boston Clinical Research Institute Read more about ICON Forms Strategic Alliance With Boston Clinical Research Institute
Investigative Sites Worldwide Rate ICON as a Top CRO According to Industry Survey Read more about Investigative Sites Worldwide Rate ICON as a Top CRO According to Industry Survey
ICON Reports First Quarter 2011 Revenue up 5% to $229 Million and EPS of 21c Read more about ICON Reports First Quarter 2011 Revenue up 5% to $229 Million and EPS of 21c
ICON and ACRONET Sign Alliance Agreement in Japan Read more about ICON and ACRONET Sign Alliance Agreement in Japan
ICON Reports Full-Year 2010 Revenue of $900m and EPS of $1.44 Read more about ICON Reports Full-Year 2010 Revenue of $900m and EPS of $1.44
